evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).

1 finding from 1 review

Negative pressure wound therapy vs standard dressing

Mortality (proportion of participants dying in each group at · adult patients with surgical wounds healing by primary closure

Negative pressure wound therapy showed no clear difference in mortality (proportion of participants dying in each group at compared with standard dressing (low certainty).

1 finding from 1 review

Negative pressure wound therapy vs standard dressing

Surgical site infection · adult patients with surgical wounds healing by primary closure

Negative pressure wound therapy probably leads to lower surgical site infection (proportion of participants in each group… compared with standard dressing (moderate certainty).

1 finding from 1 review

Negative pressure wound therapy vs standard dressing

Wound dehiscence · adult patients with surgical wounds healing by primary closure

Negative pressure wound therapy showed no clear difference in dehiscence (proportion of participants in each group with wound… compared with standard dressing (moderate certainty).

1 finding from 1 review

Negative pressure wound therapy vs standard dressing

Seroma (proportion of participants in each group with seroma; · adult patients with surgical wounds healing by primary closure

Negative pressure wound therapy showed no clear difference in seroma (proportion of participants in each group with seroma; compared with standard dressing (low certainty).

1 finding from 1 review